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Abstract
Background: Pre-term pre-eclampsia is a major cause of maternal and perinatal morbid-
ity and mortality worldwide. A multi-centre randomized–controlled trial has shown that
first-trimester screening followed by treatment of high-risk women with aspirin reduces
the risk of pre-term pre-eclampsia. However, the biomarkers currently employed in risk
prediction are only weakly associated with the outcome.
Methods: We conducted a case–cohort study within the Pregnancy Outcome Prediction
study to analyse untargeted maternal serum metabolomics in samples from 12, 20, 28
and 36 weeks of gestational age (wkGA) in women with pre-eclampsia delivering at term
(n¼165) and pre-term (n¼ 29), plus a random sample of the cohort (n¼ 325). We used
longitudinal linear mixed models to identify candidate metabolites at 20/28 wkGA that
differed by term pre-eclampsia status. Candidates were validated using measurements
at 36 wkGA in the same women. We then tested the association between the 12-, 20-
and 28-wkGA measurements and pre-term pre-eclampsia. We externally validated the
association using 24- to 28-wkGA samples from the Born in Bradford study (25 cases and
953 controls).
Results: We identified 100 metabolites that differed most at 20/28 wkGA in term
pre-eclampsia. Thirty-three of these were validated (P< 0.0005) at 36 wkGA. 4-
Hydroxyglutamate and C-glycosyltryptophan were independently predictive at 36 wkGA
of term pre-eclampsia. 4-Hydroxyglutamate was also predictive (area under the receiver
operating characteristic curve, 95% confidence interval) of pre-term pre-eclampsia
at 12 (0.673, 0.558–0.787), 20 (0.731, 0.657–0.806) and 28 wkGA (0.733, 0.627–0.839).
VC The Author(s) 2019. Published by Oxford University Press on behalf of the International Epidemiological Association. 1
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The predictive ability of 4-hydroxyglutamate at 12 wkGA was stronger than two existing
protein biomarkers, namely PAPP-A (0.567, 0.439–0.695) and placenta growth factor
(0.589, 0.463–0.714). Finally, 4-hydroxyglutamate at 24–28 wkGA was positively associ-
ated with pre-eclampsia (term or pre-term) among women from the Born in Bradford
study.
Conclusions: 4-hydroxyglutamate is a novel biochemical predictor of pre-eclampsia that
provides better first-trimester prediction of pre-term disease than currently employed
protein biomarkers.
Key words: Metabolomics, risk prediction, pre-eclampsia, pregnancy, cohort study
Introduction
Pre-eclampsia is a multisystem disorder of human preg-
nancy manifested by acquired hypertension plus involve-
ment of other systems including the kidney, liver, brain
and platelets.1 Pre-eclampsia is a major determinant of the
global burden of disease through effects on the mother and
infant. Death of the mother is primarily a feature of low-
and middle-income countries2 but hypertensive disorders
were a common cause of obstetric Intensive Therapy Unit
admissions in a UK-based study.3 Hypertensive disorders
of pregnancy are a major cause of perinatal morbidity and
mortality worldwide, being a factor in about 10–20% of
perinatal deaths4 and one of the major causes of iatrogenic
prematurity.5
The ASPRE trial demonstrated that use of 150 mg of as-
pirin, given daily and commenced at between 11 and
14 weeks of gestational age (wkGA), reduced the risk of
pre-term delivery due to pre-eclampsia by 62% in women
who screened as high-risk in the first trimester.6 The
ASPRE trial used a predictive algorithm that included ma-
ternal serum levels of placenta growth factor (PlGF) and
pregnancy-associated plasma protein A (PAPP-A) in addi-
tion to maternal factors, mean arterial pressure and uterine
artery pulsatility index. However, the rate of pre-term birth
due to pre-eclampsia was only 4.3% in the placebo group,
reflecting a high false-positive rate. The aim of the present
study was to identify novel biochemical predictors of pre-
eclampsia. We performed a case–cohort study using samples
from the Pregnancy Outcome Prediction (POP) study and
performed metabolomic profiling of maternal serum sam-
ples collected at 12, 20, 28 and 36 wkGA, comparing
women who subsequently delivered with a diagnosis of pre-
eclampsia with a random sample of women who did not
have pre-eclampsia. We used a case–control study of sam-
ples from Born in Bradford (BiB), a highly demographically
different cohort, for external validation.
Methods
Identification and validation of metabolic markers
Figure 1 illustrates an overview of the approach employed
to identify and validate novel metabolic predictors of
pre-eclampsia. Identification of candidate metabolites was
followed by two steps of internal validation, the first using
repeated metabolite measurements from different gesta-
tional ages from the same cases and the second using differ-
ent cases. This was followed by validation in an external
cohort.
Key Messages
• Discovery of new biomarkers associated with pre-term pre-eclampsia could lead to improved risk prediction and iden-
tification of women who are most likely to benefit from preventive treatment.
• We conducted a case–cohort study to identify candidate metabolites from maternal serum that are predictive of pre-
eclampsia and we validated the findings internally and in an external cohort.
• We identified a single metabolite, 4-hydroxyglutamate, which is strongly associated with pre-eclampsia and the asso-
ciation is similar in two demographically different cohorts.
• 4-Hydroxyglutamate provides better first-trimester prediction of pre-term pre-eclampsia than currently employed
biomarkers.
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Study design
The POP study was a prospective cohort study of unse-
lected nulliparous women with a singleton pregnancy at-
tending the Rosie Hospital, Cambridge, UK, between
January 2008 and July 2012. The design has been previ-
ously described.7–9 Participants had phlebotomy and fetal
biometry at 12, 20, 28 and 36 wkGA and outcome data
were retrieved through individual review of each patient’s
case record and by linkage to electronic databases. Ethical
approval was obtained from the Cambridgeshire 2
Research Ethics Committee (reference number 07/H0308/
163). All study participants gave written informed consent.
This study is reported according to the STARD 2015
guidelines for reporting diagnostic accuracy studies (http://
www.stard-statement.org/) and we have included a com-
pleted STARD checklist (available as Supplementary data
at IJE online).
A case–cohort design within the POP study was used in
the present analysis (study outline, available as
Supplementary data at IJE online). In brief, a random sam-
ple of the cohort was selected as a comparison group. Two
categories of cases were analysed in the present study: (i)
women who experienced pre-eclampsia delivering at term
and (ii) women who experienced pre-eclampsia delivering
pre-term. Pre-eclampsia was defined and classified using
the 2013 ACOG Guideline.10,11 Term pre-eclampsia cases
were compared with women from the random sub-cohort
who delivered at term without experiencing any pre-
eclampsia. Pre-term cases were compared with the all the
women in the random sub-cohort who did not experience
pre-term pre-eclampsia. Classification of pre-eclampsia
was performed blind to the results of the biochemical
analyses.
External validation: the BiB cohort
The BiB cohort is described in detail elsewhere.12,13
Recruitment to this study was conducted between 2007
and 2011 and included 12 453 women having 13 776 preg-
nancies. The study was initiated in light of concerns about
high rates of childhood morbidity and mortality in
Bradford (a multi-ethnic city in the north of England with
a high level of socio-economic deprivation). The BiB study
recruited a population that was profoundly different in its
demographic characteristics compared with the POP study,
in terms of ethnicity (40 vs 93% White European ethnicity,
respectively), parity (40 vs 100% nulliparous, respectively)
and socio-economic deprivation (68 vs 0% living in an
area of the highest quintile of socio-economic deprivation
in England, respectively). All women in the cohort, except
those with pre-existing diabetes, were invited to attend
for a glucose-tolerance test at 24–28 wkGA, with 85%
completing and having valid test data. Pre-eclampsia was
defined using all measurements of blood pressure and pro-
teinuria extracted from antenatal records and applying
the International Society for the Study of Hypertension in
Pregnancy criteria to these.14 Those without a documented
pre-eclampsia status were excluded from the analysis
(n¼ 22).
Biochemical analyses
Metabolomic analysis was performed by Metabolon
(Research Triangle Park, NC, USA), blinded to the
patients’ clinical information and pregnancy outcome.
In the POP study, analysis batches contained 36 maternal
serum samples each and all samples from the same woman
were included in the same batch. Batches were designed so
that the proportion of samples from cases and controls was
the same in all batches. Ultrahigh Performance Liquid
Chromatography-Tandem Mass Spectroscopy (UPLC-MS/
MS) was used as the analysis platform (metabolomics pro-
filing details, available as Supplementary data at IJE on-
line). Metabolite concentrations were quantified using
area-under-the-curve of primary MS ions and were
expressed as the multiple of the median value for all
batches processed on the given day; 1193 untargeted
metabolites were measured from each sample: 837 of
known structural identity and 356 of unknown structural
identity. Measurement of protein levels [PAPP-A, PlGF
and fms-like tyrosine kinase 1 (sFlt-1)] was performed on
Figure 1. Schematic outline for identification and validation of predic-
tive metabolites. PE, pre-eclampsia; wkGA, weeks of gestational age;
POP, Pregnancy Outcome Prediction; BiB, Born in Bradford.
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maternal serum using the Roche Cobas e411 immunoassay
platform, as previously described.11 Samples from the BiB
study were sent separately to Metabolon and the approach
to analysis was identical to that used in the POP study.
Metabolomics analysis was performed on ethylenediamine
tetraacetic acid (EDTA) plasma samples from 1000
women, selected randomly from women who had com-
pleted the glucose-tolerance test, had stored fasting plasma
and were of either White British or Pakistani origin,
reflecting the two largest homogenous ethnic groups and
comprising 84% of the participants.
Statistical analysis
Analyses in the POP study were predefined in an analysis
plan (available as Supplementary data at IJE online).
Scaled imputed metabolite values (multiples of the median)
were log-transformed. Initial identification of metabolites
associated with term pre-eclampsia involved fitting longi-
tudinal linear mixed models for each metabolite using
measurements from 12, 20 and 28 wkGA, to generate a
difference in the metabolite means and associated P-value
in the maternal serum at 20 and/or 28 wkGA (composite
chi-squared test) comparing term pre-eclampsia cases and
controls. We included interaction terms between term pre-
eclampsia and gestational age to identify these differences.
The metabolites were then ranked by the composite P-
value at 20/28 wkGA. Excess of low P-values was tested
using a one-sample Kolmogorov–Smirnov test against the
theoretical random distribution of P-values between 0 and
1. Initial validation used the 36-wkGA sample in the
same women and differences between cases and controls
were assessed using a linear-regression model between the
metabolite and term pre-eclampsia status. Analysis of the
36-wkGA sample employed a Bonferroni correction to the
P-value with the aim of minimizing false-positive results.
Forward-stepwise logistic regression (P< 0.05 for entry
and P< 0.1 for removal) was then used to select indepen-
dent metabolites for the prediction of term pre-eclampsia,
with inclusion of known predictors: maternal age, body
mass index (BMI) and the log-transformed sFlt-1:PlGF
ratio.
The log-transformed values of the selected metabolites
were turned into z (standard deviation) scores to enable
direct comparison between the metabolites. Associations
between selected metabolites and pre-eclampsia outcomes
were reported using odds ratios (ORs) per 1 standard
deviation higher metabolite value with 95% confidence
intervals (CIs).
Prediction of pre-term pre-eclampsia was assessed using
the area under the receiver operating characteristic (ROC)
curve (AUC). In the presence of multiple predictors, the
AUC was calculated from the predicted probability gener-
ated by a multivariable logistic-regression model. The
AUC was estimated using 1000-fold bootstrapping to
avoid optimism through overfitting.15 Assessing the added
predictive value of a variable was quantified using the
change in the AUC and was also assessed by the likelihood
ratio test comparing models with and without the given
variable. Sensitivity and positive predictive value were
reported for a 10% screen positive rate. Positive and nega-
tive predictive values were calculated using weighting
of the comparison group by the inverse of the sampling
fraction.
The association with known maternal predictors of pre-
term pre-eclampsia was quantified using a previously de-
scribed competing risks time-to-event analytic model.6 The
maternal variables included in this model were age, height,
ethnicity, chronic hypertension, systemic lupus erythema-
tosus or anti-phospholipid syndrome and conception by in
vitro fertilization (all women were nulliparous and there-
fore additional coefficients for parous women with or
without previous pre-eclampsia were not used). In women
without chronic hypertension, weight and diabetes status
were also used (family history of pre-eclampsia was not
recorded in the POP study and the value was imputed to
none). The output of this model is the predicted gestational
age of pre-eclampsia (PGAPE), where the risk of pre-
eclampsia is higher in women with lower values. PGAPE
was calculated using the data available at the 12-wkGA
visit and its association with pre-term pre-eclampsia was
estimated separately at 12, 20 and 28 wkGA for the subset
of women who had a serum sample available at the given
gestational time point.
External validation was performed using samples
from the BiB cohort. The scaled, imputed metabolite con-
centrations of 4-hydroxyglutamate were log-transformed
to improve normality and scaled to z scores. The associa-
tion between 4-hydroxyglutamate and pre-eclampsia was
reported using OR per 1 standard deviation higher metab-
olite value with 95% CIs.
All statistical analysis employed Stata 15.1 and R 3.4.4.
Results
The characteristics of the groups from the POP study are
summarized in Table 1. Women who delivered with pre-
eclampsia at term were induced more often compared with
the control group. Women who delivered with pre-eclamp-
sia pre term had a pre-labour caesarean delivery more of-
ten compared with the control group and their babies were
smaller at birth. Maternal BMI was higher and education
level lower in both groups of cases than in the controls.
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We excluded 356 metabolites of unknown structural
identity and 8 xenobiotic metabolites that had too little
variation to be analysed, leaving 829 metabolites for
the analysis. A plot of the composite P-values indicated
an excess of low values (Kolmogorov–Smirnov test
P< 0.001), suggesting that there was an association be-
tween the metabolite values at 20/28 wkGA and the risk
of term pre-eclampsia (Figure 2). The 100 metabolites
with the lowest P-values (<0.032) were selected for fur-
ther study.
Table 1. Characteristics of the POP study cohort in the metabolomics analysis of pre-eclampsia
Characteristic PE term (N¼165) PE pre-term (N¼29) Controls without pre-term PE (N¼323)
Maternal characteristics
Age, years 30 (26 to 34) 28 (23 to 33) 30 (27 to 33)
Age stopped FTE 21 years 75 (45%) 8 (28%) 177 (55%)
Missing 5 (3%) 1 (3%) 2 (1%)
Height, cm 165 (160 to 168) 163 (158 to 166) 165 (161 to 169)
BMI, kg/m2 26 (23 to 32) 28 (26 to 30) 24 (22 to 28)
Smoker 6 (4%) 1 (3%) 15 (5%)
Any alcohol consumption 7 (4%) 0 (0%) 12 (4%)
Deprivation, score 8.91 (5.56 to 13.59) 9.66 (5.68 to 11.85) 8.53 (5.95 to 14.18)
Deprivation, rank 25246 (19634 to 29324) 24266 (21549 to 29179) 25727 (19039 to 28872)
Deprivation rank quintile
1 (most deprived) 0 (0%) 0 (0%) 0 (0%)
2 13 (8%) 1 (3%) 20 (6%)
3 26 (16%) 5 (17%) 64 (20%)
4 45 (27%) 13 (45%) 79 (24%)
5 (least deprived) 73 (44%) 10 (34%) 148 (46%)
Missing 8 (5%) 0 (0%) 12 (4%)
White ethnicity 157 (95%) 26 (90%) 302 (94%)
Missing 1 (1%) 1 (4%) 6 (2%)
Married 105 (64%) 22 (76%) 232 (72%)
Diabetes
Type 1 or type 2 DM 2 (1%) 3 (10%) 0 (0%)
Gestational DM 11 (7%) 1 (3%) 11 (3%)
Essential HT 35 (21%) 12 (41%) 9 (3%)
Pre-existing renal disease 3 (2%) 1 (3%) 2 (1%)
Birth outcomes
Birthweight, g 3390 (3050 to 3760) 2130 (1600 to 2580) 3445 (3100 to 3775)
Birthweight, centile 45 (24 to 67) 17 (8 to 44) 47 (23 to 68)
Gestational age, weeks 39.9 (38.6 to 40.9) 35.3 (33.3 to 36.3) 40.3 (39.3 to 41.3)
Female fetal sex 72 (44%) 16 (55%) 165 (51%)
Induction of labour 106 (64%) 7 (24%) 114 (35%)
Mode of delivery
Spontaneous vaginal 36 (22%) 7 (24%) 161 (50%)
Assisted vaginal 51 (31%) 0 (0%) 68 (21%)
Intra-partum caesarean 55 (33%) 3 (10%) 59 (18%)
Pre-labour caesarean 22 (13%) 19 (66%) 33 (10%)
Missing 1 (1%) 0 (0%) 2 (1%)
In total, 4212 women completed the POP study. After the exclusion of miscarriages, fetal deaths prior to 23 wkGA and terminations (total n¼ 29) and women
who did not have any blood samples available (n¼ 6), 4177 women remained in the cohort and the random sub-cohort (n¼ 325) was selected from this popula-
tion. Data are expressed as median (IQR) or n (%) as appropriate. For fields where there is no category labelled ‘missing’, data were 100% complete.
Maternal age was defined as age at recruitment. All other maternal characteristics were defined by self-report at the 20-wkGA questionnaire, from examination
of the clinical case record or linkage to the hospital’s electronic databases. The weight measurement used in the BMI calculation was made at the 12-wkGA visit.
Socio-economic status was quantified using the Index of Multiple Deprivation (IMD) 2007,16 which is based on census data from the area of the mother’s post-
code. Deprivation score is the combined sum of the weighted, exponentially transformed domain rank of the domain score and higher values indicate more depri-
vation. Conversely, the most deprived area has the lowest rank (¼ 1) and the least deprived area has the highest rank (¼ 32 482). A national reference distribution
from 201017 has been used to analyse the rank in quintiles (1¼most deprived, 5¼ least deprived), enabling a comparison with the Born in Bradford study. Pre-
eclampsia was defined on the basis of the 2013 ACOG criteria. FTE, full-time education; BMI, body mass index; DM, diabetes mellitus; PE, pre-eclampsia; HT,
hypertension.
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Using a Bonferroni-corrected threshold (i.e. P< 0.0005),
33 of the 100 metabolites were different between term cases
and controls at 36 wkGA (Supplementary Table 1, available
as Supplementary data at IJE online). Many of these
metabolites were correlated (Supplementary Table 2, avail-
able as Supplementary data at IJE online). The variables
independently associated with term pre-eclampsia in the for-
ward-stepwise logistic regression were maternal BMI and
age, the sFlt-1:PlGF ratio, 4-hydroxyglutamate, C-glycosyl-
tryptophan and 1-palmitoyl-2-linoleoyl-GPE (16:0/18:2).
We then determined the extent to which each one of
them at 36 wkGA added to the prediction achieved by the
sFlt1:PlGF ratio, a currently employed biomarker for pre-
eclampsia. The AUC for the sFlt-1:PlGF ratio at 36 wkGA
on its own was 0.806. The single metabolite that enhanced
prediction most was 4-hydroxyglutamate, which increased
the AUC by 0.028 (AUC¼ 0.834). The second most infor-
mative metabolite, C-glycosyltryptophan, further improved
the AUC by 0.014 (AUC¼0.848). The remaining metabo-
lite, 1-palmitoyl-2-linoleoyl-GPE (16:0/18:2), did not further
improve the AUC (increase¼ 0.001, AUC¼ 0.849).
We sought to evaluate these two candidates further as
predictors of pre-eclampsia resulting in pre-term delivery.
Plotting each metabolite by quintiles (Figure 3) revealed
strong positive associations between 4-hydroxyglutamate
measured at 12, 20 and 28 wkGA and pre-term pre-
eclampsia, whereas C-glycosyltryptophan was only
strongly associated with pre-term pre-eclampsia when
measured at 28 wkGA. When the two metabolites were ad-
justed for each other, the strong positive associations be-
tween 4-hydroxyglutamate at 12, 20 and 28 wkGA and the
risk of pre-term pre-eclampsia remained (Table 2). In rela-
tion to C-glycosyltryptophan and pre-term pre-eclampsia,
there was no sufficient evidence for an association at 12 or
20 wkGA, but there was still a strong association at
28 wkGA. Therefore, in further analysis, we focused on the
predictive ability of 4-hydroxyglutamate at 12 and
20 wkGA and of both 4-hydroxyglutamate and C-glycosyl-
tryptophan at 28 wkGA.
At 12 wkGA, the predictive ability (AUC, 95% CI) of 4-
hydroxyglutamate for the risk of pre-term pre-eclampsia
(0.673, 0.558–0.787) was stronger than either PAPP-A
(0.567, 0.439–0.695) or PlGF (0.589, 0.463–0.714). We
then examined the predictive ability of combinations of
biomarkers with a previously described model to predict
the risk of pre-term pre-eclampsia using maternal charac-
teristics (Table 3),6 where the output (PGAPE) was in-
versely associated with the risk of disease. PGAPE on its
own was highly predictive of the risk of pre-term pre-
eclampsia (0.863, 0.798–0.927). 4-Hydroxyglutamate en-
hanced prediction achieved using PGAPE (increase in
AUC¼ 0.019). In contrast, adding PAPP-A and PlGF to
models containing only PGAPE or PGAPE and 4-hydroxy-
glutamate resulted in negligible changes in the AUC. At
20 wkGA, 4-hydroxyglutamate also enhanced prediction
of pre-term pre-eclampsia and both 4-hydroxyglutamate
and C-glycosyltryptophan enhanced prediction at
28 wkGA (Supplementary Tables 3 and 4, available as
Supplementary data at IJE online). We have also presented
a ROC curve analysis for the addition of 4-hydroxygluta-
mate to the sFlt-1:PlGF ratio at 28 wkGA in the prediction
of pre-term pre-eclampsia and at 36 wkGA in the predic-
tion of term pre-eclampsia (Figure 4).
Using a 10% screen positive rate, adding first-trimester
4-hydroxyglutamate levels to PGAPE increased the sensi-
tivity for pre-term pre-eclampsia from 51.7 to 55.2% and
increased the positive predictive value from 6.1 to 6.8%,
although the CIs were wide (Supplementary Table 5, avail-
able as Supplementary data at IJE online). Nevertheless,
using the point estimates, the effect of adding 4-hydroxy-
glutamate to PGAPE was to reduce the ratio of false posi-
tives to true positives by 11%.
Finally, we performed external validation analysing ma-
ternal EDTA plasma metabolomics performed on samples
obtained at 24–28 wkGA in the BiB cohort, comparing 25
women who subsequently had a pregnancy complicated by
pre-eclampsia and 953 women who did not. The character-
istics of the two groups were tabulated (Supplementary
Table 6, available as Supplementary data at IJE online).
We found that 4-hydroxyglutamate levels were higher in
women who went on to develop pre-eclampsia
(OR¼ 1.43, one-sided P¼ 0.029) and the magnitude of the
association was comparable to that observed in the POP
study between 4-hydroxyglutamate at 28 wkGA and the
risk of any subsequent pre-eclampsia (OR¼ 1.51).
Figure 2. Distribution of P-values from the composite chi-squared test
(two-sided) for the measurements at 20/28 weeks of gestational age
(wkGA). The P-values of 829 metabolites with a known structural iden-
tity were calculated from the test for interaction between term pre-
eclampsia and gestational age.
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Discussion
The ASPRE multi-centre randomized–controlled trial
reported in 2017 that 150 mg aspirin given at night from
11–14 through to 36 wkGA reduced the risk of pre-term
delivery with a diagnosis of pre-eclampsia by 62%. The
study’s approach was to target aspirin to women identified
as at high risk of pre-term pre-eclampsia as assessed by a
model combining maternal characteristics, protein bio-
markers and uterine artery Doppler flow velocimetry. The
main finding of the present study is that first-trimester ma-
ternal serum levels of 4-hydroxyglutamate were more
strongly associated with the risk of pre-term pre-eclampsia
than the two protein biomarkers employed in the ASPRE
algorithm: PAPP-A and PlGF. Moreover, unlike the protein
biomarkers, 4-hydroxyglutamate levels were associated
with pre-term pre-eclampsia independently of maternal
characteristics. To our knowledge, this is the first report of
any association between 4-hydroxyglutamate and an ac-
quired human disease.
We used a discovery-based (i.e. untargeted) method to
identify the association with 4-hydroxyglutamate. The
only previously described use for measurement of 4-
hydroxyglutamate in assessing disease risk, to our knowl-
edge, has been to aid the diagnosis of primary hyperoxalu-
ria type 318 and there are very few published data that
could shed light on the biological basis for a link with pre-
eclampsia. 4-Hydroxyglutamate is formed from 4-hy-
droxyproline inside mitochondria and the primary source
Figure 3. The proportion of pre-term pre-eclampsia cases (95% confidence interval) by the quintile of 4-hydroxyglutamate and C-glycosyltryptophan
at 12, 20 and 28 wkGA. (A) 4-hydroxyglutamate at 12 wkGA; (B) C-glycosyltryptophan at 12 wkGA; (C) 4-hydroxyglutamate at 20 wkGA; (D) C-glycosyl-
tryptophan at 20 wkGA; (E) 4-hydroxyglutamate at 28 wkGA; (F) C-glycosyltryptophan at 28 wkGA. The non-cases were weighted by the inverse of the
random sub-cohort sampling fraction (¼ 12.85) to obtain the proportion of cases of pre-term pre-eclampsia. There were no cases in the first quintile
of 4-hydroxyglutamate at 20 wkGA and therefore the 95% confidence interval could not be calculated. Two-sided logistic-regression P-values are
given for the linear trend between the quintile and log-odds of pre-term pre-eclampsia. PE, pre-eclampsia; wkGA, weeks of gestational age.
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of 4-hydroxyproline is collagen (dietary and endoge-
nous).18 Hence, high levels of 4-hydroxyglutamate could
result from increased collagen turnover and the release of
4-hydroxyproline. However, high levels could also result
from decreased metabolism of 4-hydroxyglutamate. Its
transamination by the mitochondrial enzyme Glutamic-
Oxaloacetic Transaminase 2, GOT2, yields glutamate and
4-hydroxy-2-oxo-glutarate.19 Finally, it is well recognized
that control of placental exchange of glutamate and gluta-
mine has an important role in promoting normal preg-
nancy20 and it is possible that the association between 4-
hydroxyglutamate and pre-eclampsia is due to a currently
unrecognized metabolic pathway.
Although further studies will be required to delineate
the mechanism linking maternal serum levels of 4-hydrox-
yglutamate to pre-eclampsia, the evidence supporting the
association is strong. First, 4-hydroxyglutamate was identi-
fied on the basis of its association with term pre-eclampsia
using the 12-, 20- and 28-wkGA samples. The association
was much stronger in the initial validation stage at
36 wkGA than at earlier gestational ages. By using analysis
of the cases of term pre-eclampsia to identify candidate re-
mote markers of the disease, we reduced the number of
metabolites being tested in our pre-term cases to just two,
namely 4-hydroxyglutamate and C-glycosyltryptophan.
The association between 4-hydroxyglutamate and pre-
term pre-eclampsia was strong at all three gestational time
points (i.e. 12, 20 and 28 wkGA). The results from these
internal validation steps suggest the associations are un-
likely to be chance findings. Finally, the generalizability of
the finding was confirmed by external validation for the as-
sociation with pre-eclampsia leading to either pre-term or
term birth in the BiB cohort. The populations of the POP
study and the BiB study differ profoundly in terms of par-
ity, ethnicity and socio-economic status. The observation
that the association was comparable in two such dissimilar
populations provides strong evidence for the generalizabil-
ity of the current findings. It is also highly plausible that
Table 2. Odds ratios (95% confidence intervals) and P-value of the unadjusted and adjusted metabolite measurements (a) at 12,
20 and 28 wkGA in relation to pre-term pre-eclampsia (n¼ 29) and (b) at 36 wkGA in relation to term pre-eclampsia (n¼165) in
the case–cohort sample (total n¼504)
Odds ratios (95% confidence intervals) and P-value
Metabolite Model 12 wkGA and
pre-term PE
20 wkGA and
pre-term PE
28 wkGA and
pre-term PE
36 wkGA and
term PE
4-hydroxyglutamate Unadjusted 2.04 (1.37 to 3.04) 2.38 (1.46 to 3.88) 2.37 (1.53 to 3.66) 2.24 (1.70 to 2.96)
P¼0.0004 P¼0.0005 P¼0.0001 P<0.0001
Adjusted 1.99 (1.33 to 2.98) 2.40 (1.45 to 3.98) 2.05 (1.29 to 3.26) 1.87 (1.42 to 2.47)
P¼0.0009 P¼0.0007 P¼0.0024 P<0.0001
C-glycosyltryptophan Unadjusted 1.48 (0.97 to 2.24) 1.58 (1.08 to 2.33) 2.26 (1.48 to 3.45) 2.67 (2.05 to 3.48)
P¼0.067 P¼0.020 P¼0.0001 P<0.0001
Adjusted 1.37 (0.88 to 2.13) 1.56 (1.05 to 2.33) 1.98 (1.27 to 3.10) 2.55 (1.92 to 3.38)
P¼0.17 P¼0.029 P¼0.0027 P<0.0001
Odds ratios are given for 1 standard deviation increase in the log-transformed metabolite. Adjusted models are only adjusted for the other metabolite. All P-val-
ues are two-sided. wkGA, weeks of gestational age; PE, pre-eclampsia.
Table 3. Prediction of pre-term pre-eclampsia at 12 wkGA
Model AUC Change in AUC P-valuea
PGAPE þ PAPP-A þ PlGF þ 4-hydroxyglutamate 0.887 – –
PGAPE þ 4-hydroxyglutamate 0.882 –0.005 0.14
PGAPE þ PAPP-A þ PlGF 0.859 –0.028 0.023
PGAPE 0.863 –0.024 0.035
4-hydroxyglutamate 0.673 –0.214 <0.0001
PAPP-A þ PlGF 0.539 –0.348 <0.0001
aCompared with full model using likelihood ratio test of nested logistic-regression models. Where the model included more than one predictor, the AUC was
corrected for optimism using 1000-fold bootstrapping.
PGAPE ¼ the predicted gestational age of pre-eclampsia. This is the output of the competing risks time-to-event model employed in the ASPRE study (see
Rolnik et al., 20176 for details).
AUC, area under the ROC curve; wkGA, weeks of gestational age; PAPP-A, pregnancy-associated plasma protein A; PlGF, placenta growth factor.
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true associations would be apparent in diverse human
populations.
Although the focus of the current analysis was on first-
trimester predictors of pre-eclampsia leading to pre-term
delivery, prediction of pre-eclampsia in late pregnancy is
also important. In women presenting with signs or symp-
toms, testing can inform the use of expensive and poten-
tially harmful interventions, such as hospital admission,
administration of steroids, transfer to a tertiary unit or de-
livery.21 In asymptomatic women, the estimated risk could
be used to inform the intensity of antenatal surveillance.11
In late pregnancy, the ratio of two biomarkers, sFlt-1 and
PlGF, has been shown to have high negative predictive
value in the context of women presenting with symptoms
or signs of pre-eclampsia.21 However, the sFlt-1:PlGF ratio
is not yet recommended as a ‘rule-in’ test for the disease.22
Moreover, when combined with maternal risk factors as a
screening test for the disease in later pregnancy in nullipa-
rous women, about 25% of the population fall into an in-
determinate category of risk.11 We found that 4-
hydroxyglutamate enhanced prediction of pre-term pre-
eclampsia when measured at 20 and 28 wkGA and of term
pre-eclampsia when measured at 36 wkGA. Hence, mea-
surement of this metabolite might have utility in the pre-
diction of pre-eclampsia in later pregnancy, but
improvement in prediction would have to be assessed in
further studies. In the present study, we analysed pre-term
and term pre-eclampsia cases separately to reduce the risk
of false discovery. However, there are significant differen-
ces in the pathophysiology of pre-term and term disease23
and future studies could also address differences in metab-
olite levels directly comparing pre-term and term cases.
Additional studies might also address whether 4-hydroxy-
glutamate is also associated with the risk of other cardio-
vascular or renal conditions outside pregnancy, given that
women with pre-eclampsia have an increased risk of both
in later life.24,25
It is well recognized that, in the application of ‘omics’
technologies, there is the potential for the generation of
false-positive results. Typically, the number of potential
predictors of disease is very large in relation to the number
of cases studied, which leads to an increased risk of over-
optimistic prediction of associations.15,26 In addition to the
number of predictors, the out-of-sample performance of
the prediction model depends on the total sample size and
the events fraction, i.e. the proportion of cases in the sam-
ple.27 The present study was relatively large, although the
ratio of cases of term pre-eclampsia to candidate metabo-
lites was <1. We overcame this issue by using multiple
sampling time points in the POP study and by performing
external validation in the BiB study (Figure 1).
A recent review of 28 small studies on the metabolomics
of pre-eclampsia could not identify a single validated
metabolite demonstrating utility as a pre-eclampsia bio-
marker.28 Included in the review was a metabolomic study
of 50 cases of pre-term pre-eclampsia and 108 controls
that identified five possible biomarkers,29 although none
of these was associated with pre-term pre-eclampsia in the
POP study (data available from authors on request). These
were most likely false discoveries due to a single time frame
Figure 4. Receiver operating characteristic curve (ROC) analysis of the
sFlt-1:PlGF ratio and 4-hydroxyglutamate in relation to pre-term and
term pre-eclampsia. The ROC curve for (A) addition of 4-hydroxygluta-
mate to sFlt-1:PlGF ratio at 28 wkGA and pre-term pre-eclampsia and (B)
addition of 4-hydroxyglutamate to sFlt-1:PlGF ratio at 36 wkGA and
term pre-eclampsia. Dashed lines represent the sFlt-1:PlGF ratio meas-
urements on their own and solid lines represent the models that include
both sFlt-1:PlGF ratio and 4-hydroxyglutamate. The P-value was
obtained from the De Long test for equality between the AUCs. AUC,
area under the ROC curve; wkGA, weeks of gestational age.
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of blood sampling and a small total number of cases, i.e.
50 blood samples from 50 cases. In contrast, we analysed
the results from 194 cases and exploited multiple tempo-
rally separated sampling points from the same women. The
rigorous approach to selection likely explains the fact that
we could replicate the association in a markedly different
population.
In a review article published over 10 years ago, Carty
and colleagues30 suspected that it was unlikely that a single
marker would turn out to accurately predict pre-eclampsia.
Instead, a combination of different types of risk factors
would have to be considered. Addition of a single weakly
predictive biomarker into an existing prediction model
might not result in a clinically meaningful improvement
in prediction, as has been shown, e.g. in the field of
cardiovascular epidemiology.31 However, even a moderate
increase in the AUC combined with carefully chosen
thresholds might help in reclassifying women into risk
categories and in targeting antenatal monitoring better.
Conclusions
We conclude that 4-hydroxyglutamate is a novel biomarker
for pre-eclampsia. The strength of association means that it
may enhance prediction of the disease in the clinical contexts
where protein biomarkers are already employed.
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